Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12296397 | 0.91 | TDP1 (0.56) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E | |
| SCHEMBL2862707 | 0.86 | CYP2C9 (0.52) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E | |
| SCHEMBL4159314 | 0.83 | MAPK1 (0.48) | CYP2C19ALDH1A1KDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL2863159 | 0.82 | TDP1 (0.56) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E | |
| SCHEMBL8741137 | 0.80 | CYP2C19 (0.70) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E | |
| SCHEMBL6223853 | 0.78 | ALDH1A1 (0.46) | CYP2C19ALDH1A1KDM4EMAPK1CYP1A2 | |
| SCHEMBL6141860 | 0.78 | TDP1 (0.68) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E | |
| SCHEMBL344526 | 0.77 | CYP2C9 (0.72) | CYP2C19CYP2C9TDP1ALDH1A1PRMT3 | |
| SCHEMBL13450925 | 0.77 | KDM4E (0.39) | CYP2C19ALDH1A1KDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL3404460 | 0.75 | PRMT3 (0.48) | CYP2C19CYP2C9TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CYP2C19 1259/4885CYP2C9 1162/4885TDP1 2886/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CYP2C19 1259/4885CYP2C9 1162/4885TDP1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.